Lilly announces phase III SEQUOIA study of pegilodecakin + FOLFOX in patients with metastatic pancreatic cancer did not meet primary endpoint of overall survival.

Eli Lilly and Company announced top-line results from its Phase III SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen. The SEQUOIA trial did not meet its primary endpoint of overall survival.

The most common Grade 3/4 adverse events occurring at a higher rate ,(greater than 5% difference) on the pegilodecakin-plus-FOLFOX arm compared to the FOLFOX arm were neutropenia, thrombocytopenia, fatigue and anemia. Detailed efficacy and safety results will be submitted for presentation at a future medical meeting.

Metastatic pancreatic cancer is one of the deadliest major cancers, with just three percent of patients in the U.S. living five years after the cancer is diagnosed. In the U.S., pancreatic cancer is the third leading cause of cancer death and is expected to become the second leading cause of cancer-related death in the next decade. Globally, pancreatic cancer is the seventh leading cause of cancer-related death.